Pulmonx Co. (NASDAQ:LUNG) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of Pulmonx Co. (NASDAQ:LUNG) have received an average rating of “Moderate Buy” from the six research firms that are covering the stock, MarketBeat Ratings reports. Two research analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $12.75.

A number of analysts have commented on the company. Stifel Nicolaus reduced their price target on Pulmonx from $17.00 to $16.00 and set a “buy” rating for the company in a research report on Thursday, October 31st. Citigroup restated a “neutral” rating and set a $7.50 target price (down previously from $17.00) on shares of Pulmonx in a research note on Wednesday, December 11th. Finally, Wells Fargo & Company dropped their price target on shares of Pulmonx from $10.00 to $8.00 and set an “equal weight” rating for the company in a research report on Wednesday, December 11th.

Insiders Place Their Bets

In other news, Director Glendon E. French III sold 20,000 shares of Pulmonx stock in a transaction dated Friday, November 22nd. The stock was sold at an average price of $6.63, for a total value of $132,600.00. Following the sale, the director now directly owns 1,071,974 shares of the company’s stock, valued at approximately $7,107,187.62. The trade was a 1.83 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Geoffrey Beran Rose sold 4,376 shares of the stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $6.18, for a total value of $27,043.68. Following the transaction, the insider now directly owns 291,057 shares of the company’s stock, valued at approximately $1,798,732.26. The trade was a 1.48 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 29,873 shares of company stock worth $193,670 in the last three months. 5.70% of the stock is owned by company insiders.

Institutional Trading of Pulmonx

Large investors have recently added to or reduced their stakes in the company. 272 Capital LP purchased a new position in shares of Pulmonx in the third quarter valued at $25,000. nVerses Capital LLC bought a new stake in shares of Pulmonx in the 3rd quarter worth about $26,000. Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Pulmonx during the 2nd quarter valued at about $37,000. SG Americas Securities LLC bought a new position in shares of Pulmonx in the 3rd quarter valued at about $102,000. Finally, Hsbc Holdings PLC purchased a new position in Pulmonx in the second quarter worth about $93,000. Institutional investors own 91.04% of the company’s stock.

Pulmonx Stock Performance

Shares of NASDAQ LUNG opened at $6.40 on Friday. Pulmonx has a 12-month low of $5.46 and a 12-month high of $14.84. The firm has a market capitalization of $252.74 million, a price-to-earnings ratio of -4.35 and a beta of 0.66. The company has a current ratio of 7.70, a quick ratio of 6.77 and a debt-to-equity ratio of 0.40. The firm has a 50 day moving average of $6.52 and a 200 day moving average of $6.88.

Pulmonx (NASDAQ:LUNG) last issued its quarterly earnings data on Wednesday, October 30th. The company reported ($0.36) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.07. The firm had revenue of $20.39 million during the quarter, compared to the consensus estimate of $20.39 million. Pulmonx had a negative net margin of 72.01% and a negative return on equity of 53.88%. During the same quarter in the previous year, the firm posted ($0.39) EPS. On average, research analysts anticipate that Pulmonx will post -1.53 earnings per share for the current year.

Pulmonx Company Profile

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.